Gastrointestinal Dysfunction
1 Irritable Bowel Syndrome Overlap
IBS and ME/CFS show profound overlap, complicating both diagnosis and treatment.
Prevalence.
- 50–90% of ME/CFS patients meet criteria for IBS (median 51%)
- Cluster analysis: 59.6% of ME/CFS patients have “abdominal discomfort syndrome”
- IBS patients have 5-fold higher odds of having CFS compared to general population
- IBS-Constipation (IBS-C) subtype shows higher ME/CFS association than IBS-Diarrhea
Clinical Significance. ME/CFS patients with comorbid IBS demonstrate:
- More severe fatigue
- Poorer appetite
- Increased abdominal pain
- Greater overall symptom burden
2 Motility Disorders
2.1 Gastroparesis
Delayed gastric emptying is common in ME/CFS and contributes significantly to symptom burden.
A 2023 gastric emptying scintigraphy study (Vasquez-Marti et al. 2023) in ME/CFS patients (n=40) demonstrated:
- 72% showed delayed liquid-phase emptying
- 38% showed delayed solid-phase emptying
- Degree of delay correlated significantly with symptom severity
- Both liquid and solid delay increased with more severe ME/CFS
- Lower proximal stomach accommodation after meals
- Larger fasting antral area (suggesting visceral hypersensitivity)
Symptom profiles resembled functional dyspepsia, though autonomic dysfunction likely contributes (cross-sectional, n=40, Medium certainty). Autonomic Connection.
Gastroparesis in ME/CFS is likely secondary to autonomic dysfunction:
- Parasympathetic dysfunction associated with delayed gastric emptying
- Vagal nerve impairment reduces gastric motility
- Sympathetic hyperactivation may inhibit digestive function
- Dysautonomia disrupts coordinated antral contractions
Symptoms.
- Early satiety (75% of ME/CFS patients)
- Postprandial fullness and bloating
- Nausea (35%)
- Abdominal pain (45%)
- Vomiting (in severe cases)
2.2 Small Intestinal Bacterial Overgrowth (SIBO)
SIBO occurs when excessive bacteria colonize the small intestine, which is normally relatively sterile. It is increasingly recognized as a major contributor to ME/CFS gastrointestinal symptoms.
A retrospective analysis of ME/CFS patients referred for breath testing found:
- 479 patients referred; 367 completed hydrogen-methane breath tests
- 48% SIBO-positive when excluding equivocal results (152/316)
- 41% SIBO-positive overall (including equivocal as negative)
- 45% SIBO-negative
- 14% equivocal
- Predictive factors: older age, IBS diagnosis
This suggests a substantial proportion of ME/CFS patients have bacterial overgrowth, though the retrospective design and referral bias (patients referred for breath testing likely had more GI symptoms) limit generalizability (retrospective chart review; 479 referred, 367 with usable results, 316 conclusive; Medium certainty) (Karhu et al. 2023). An earlier conference abstract (Pimentel et al. 2000) (Pimentel et al. 2000; n=31 CFS patients; Low certainty 0.25 — conference abstract only, not peer-reviewed as full paper) reported 77% SIBO positivity by lactulose hydrogen breath test and a double-blind RCT of neomycin versus placebo. The study was underpowered and showed no significant difference between arms; breath test normalization correlated with symptom improvement in responders. This historically early finding is consistent with the direction of the Karhu 2023 data but should be interpreted with caution given study design limitations.
Pathophysiology: Migrating Motor Complex Dysfunction.
The migrating motor complex (MMC) is a cyclic pattern of electromechanical activity that “sweeps” bacteria from the small intestine to the colon during fasting.
- MMC occurs every 90–120 minutes during fasting
- Controlled by Interstitial Cells of Cajal linking smooth muscle to enteric nervous system
- Studies suggest most patients with abnormal MMC develop duodenal bacterial overgrowth
- MMC dysfunction allows bacteria to accumulate in small intestine
Factors impairing MMC in ME/CFS:
- Enteric nervous system dysfunction: The small bowel MMC is driven autonomously by the enteric nervous system, not by the vagus nerve. Deloose et al. (Deloose et al. 2012) established that the vagus modulates gastric MMC phase III but does not regulate small bowel MMC periodicity. Consequently, enteric neuropathy—rather than vagal dysfunction—is the primary autonomic mechanism for small bowel MMC failure. Motilin and ghrelin signaling disruption are additional pathways.
- Autonomic dysfunction (gastric phase): Vagal impairment reduces gastric MMC phase III amplitude and can delay gastroduodenal propagation, but this does not account for small bowel SIBO-predisposing MMC failure directly.
- Post-infectious autoimmunity: Anti-CdtB and anti-vinculin antibodies (from prior gastroenteritis) damage Interstitial Cells of Cajal
- Chronic stress: Sympathetic activation suppresses MMC
- Hypothyroidism: Modulates enteric nervous system function
- Medications: Opioids, anticholinergics impair motility
SIBO Subtypes.
Different bacterial populations produce different gases, leading to distinct clinical presentations:
| Subtype | Gas Produced | Predominant Symptoms | Treatment Focus |
|---|---|---|---|
| Hydrogen-dominant | H2 | Diarrhea | Rifaximin |
| Methane (IMO) | CH4 | Constipation | Rifaximin + neomycin |
| Hydrogen sulfide (ISO) | H2S | Diarrhea, gas, odor | Bismuth, targeted antibiotics |
{IMO = Intestinal Methanogen Overgrowth; ISO = Intestinal Sulfide Overproduction.}
- Hydrogen-dominant: Most common; E. coli, Klebsiella, other hydrogen producers
- Methane-dominant (IMO): Archaea (Methanobrevibacter smithii) convert H2 to CH4; slows transit time, causes constipation
- Hydrogen sulfide (ISO): Sulfate-reducing bacteria; associated with diarrhea; NOT detected by standard H2/CH4 tests (requires Trio-Smart 3-gas test)
2.2.1 Hydrogen Sulfide as a Gut-Derived Mitochondrial Toxin
Hydrogen sulfide (H2S) produced by intestinal sulfate-reducing bacteria (Desulfovibrio, Bilophila wadsworthia, Fusobacterium) directly inhibits mitochondrial Complex IV (cytochrome c oxidase) by binding to its binuclear CuB/hemea3~ active site — the same site targeted by cyanide (Nicholls et al. 2013). The inhibition is biphasic and partially reversible, but at the micromolar concentrations produced by bacterial overgrowth, it chronically reduces ATP output without causing acute cell death.
In ME/CFS patients with documented gut dysbiosis, sulfate-reducing bacterial overgrowth may produce sufficient H2S to chronically inhibit Complex IV, contributing to the cellular energy deficit independently of other mitochondrial impairments. (Certainty: 0.40 — mechanism established in general biochemistry and IBS cohorts (Borisov and Forte 2021) (Villanueva-Millan et al. 2022); no ME/CFS-specific H2S measurements exist.)
Mechanistic chain: + Dysbiosis shifts microbiome toward sulfate-reducing bacteria (favoured by Western diet, dietary sulfur, impaired motility) + Sulfate-reducing bacteria produce H2S as metabolic waste (Pimenta, Bernardino, and Pereira 2024) + H2S enters portal circulation; liver clears >97% when oxygenated, but clearance drops to ~23% under hypoxic conditions (Norris et al. 2011) + Orthostatic hypoperfusion (common in ME/CFS) may reduce hepatic oxygen delivery, impairing portal H2S clearance + Systemic H2S reaches skeletal muscle, cardiac muscle, and brain mitochondria + Complex IV inhibition reduces ATP ceiling in all affected tissues
Critical nuance: H2S at physiological concentrations (low nanomolar range) is a beneficial gaseous signalling molecule with anti-inflammatory and cytoprotective properties via S-sulfhydration. The pathological mechanism requires micromolar concentrations produced by bacterial overgrowth — a dose-response relationship, not a binary toxin/non-toxin distinction (Paul, Snyder, and Kashfi 2021).
SQOR–CoQ10 link: The primary H2S clearance enzyme — sulfide quinone oxidoreductase (SQOR) — transfers electrons from H2S to coenzyme Q10 (Landry, Ballou, and Banerjee 2021). CoQ10 deficiency, which is proposed in ME/CFS and worsened by statin use, would directly impair SQOR function, creating a vicious cycle: reduced CoQ10 → impaired H2S clearance → H2S accumulation → further Complex IV inhibition → worsened energy failure.
Falsifiable prediction: ME/CFS patients with diarrhoea-predominant gastrointestinal symptoms and documented dysbiosis should show elevated breath H2S (Trio-Smart test) and elevated urinary thiosulfate compared to ME/CFS patients without GI symptoms. Dietary sulfur restriction or bismuth subsalicylate should reduce H2S markers and improve fatigue scores in this subset.
Limitations: No ME/CFS study has measured Desulfovibrio abundance, breath H2S, or SQOR activity. The mechanism is extrapolated from general biochemistry and IBS/IBD data. The SQOR–CoQ10 link is mechanistically established but not demonstrated in ME/CFS patients. Not yet replicated in any ME/CFS cohort.
Treatment implications (research-stage only): Bismuth subsalicylate has shown proof-of-concept in murine models where Desulfovibrio-derived H2S suppressed GLP-1 production via mitochondrial inhibition (Qi et al. 2024). Dietary sulfur restriction (reducing garlic, cruciferous vegetables, eggs, NAC, alpha-lipoic acid) reduced sulfidogenic pathobionts in an 8-week UC pilot (Ye et al. 2025).
Several supplements commonly recommended for ME/CFS patients contain sulfur: N-acetyl cysteine (NAC), alpha-lipoic acid (ALA), methylsulfonylmethane (MSM), and taurine. In patients with H2S-dominant dysbiosis, these supplements increase substrate availability for sulfate-reducing bacteria, potentially worsening the very mitochondrial impairment they are intended to treat. Patients reporting worsening fatigue, rotten-egg gas, or diarrhoea on sulfur-containing supplements should be evaluated for H2S-dominant SIBO before continuing.
Diagnosis: Breath Testing.
Breath testing remains the primary non-invasive diagnostic method for SIBO.
Protocol:
- Substrate: Glucose (50–75g) or lactulose (10g)
- Measurements: Every 15 minutes for 120 minutes
- End-expiratory breath samples analyzed for H2, CH4 (and H2S if available)
Interpretation:
- Hydrogen: Rise \(\geq\) 20 ppm above baseline
- Methane: \(\geq\) 10 ppm at any point
- Hydrogen sulfide: \(\geq\) 3 ppm at any point (Trio-Smart criteria)
Glucose vs Lactulose:
- Glucose absorbed in proximal small intestine (more specific for SIBO)
- Lactulose reaches colon (may yield false positives)
- Glucose preferred for diagnosis; lactulose may detect distal SIBO
A 2024 clinical practice update endorsed by the European Society of Neurogastroenterology and Motility (ESNM) and the American Neurogastroenterology and Motility Society (ANMS) raises fundamental methodological concerns about lactulose hydrogen breath testing (Kashyap et al. 2024):
- The lactulose H2 breath test (LHBT) primarily measures oro-cecal transit time, not bacterial overgrowth — normal transit ranges from 25–200 minutes, creating widespread false-positive results
- Three independent research teams found no single time point reliably discriminates IBS from healthy controls
- Diagnostic criteria have shifted repeatedly (20 ppm at 90 min → 180 min → addition of methane) without prospective validation
- Breath test normalization after antibiotic treatment does not reliably predict clinical symptom improvement
- The authors conclude: “after two decades, this hypothesis remains unproven,” and raise antimicrobial stewardship concerns about antibiotic prescribing driven by unvalidated testing
Scope of critique: This appraisal targets the SIBO-IBS hypothesis and breath test methodology. It does not negate SIBO as a pathological entity or its potential relevance to ME/CFS. The ME/CFS-specific study (Karhu 2023, (Karhu et al. 2023)) has independent limitations (retrospective, referral bias). Glucose breath testing carries fewer false-positive concerns than lactulose. Clinicians should interpret positive lactulose breath tests with caution and prioritize glucose-based protocols where available.
3 Digestive Function
Beyond motility, ME/CFS patients may have impaired digestive capacity:
- Pancreatic enzyme insufficiency: Reduced lipase, protease, amylase secretion
- Bile acid malabsorption: Impaired fat digestion; contributes to diarrhea
- Nutrient malabsorption: Consequent to SIBO, intestinal permeability, and enzyme deficiency
- Hypochlorhydria: Reduced gastric acid (sometimes from PPI overuse) predisposes to SIBO
SIBO Subtype–Specific Nutritional Deficits.
Wielgosz-Grochowska et al. (Wielgosz-Grochowska, Domanski, and Drywien 2024) (n=67 newly diagnosed SIBO patients; observational, single-centre, Medium certainty 0.45; not ME/CFS-specific) found that deficiency burden varies significantly by SIBO subtype:
- H+/M+ mixed subtype (51% of cohort): Lowest serum vitamin D, lowest serum ferritin — highest nutritional deficiency burden of all three subtypes; also had highest dietary fat intake
- M+ methane-dominant (31%): Elevated folate (bacterial production), reduced fiber intake; >70% consumed excessive fat
- H+ hydrogen-dominant (18%): Primarily reduced lactose tolerance
- All subtypes: 87–97% were below the vitamin D adequate intake threshold
These findings suggest SIBO patients with mixed H+/M+ phenotype — likely the most severe subtype — should be evaluated for vitamin D deficiency and iron depletion as a standard part of workup. Given the 48% SIBO prevalence in ME/CFS patients (Karhu 2023 (Karhu et al. 2023)), subtype-stratified nutritional assessment is clinically relevant.